Category News

AstraZeneca Advances Its Mission to Redefine Cancer Care with First Results from Four Pivotal Trials Presented at ESMO 2025

AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025 AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, set to take place from October…

Read MoreAstraZeneca Advances Its Mission to Redefine Cancer Care with First Results from Four Pivotal Trials Presented at ESMO 2025

FDA Approves Expanded Indication for RINVOQ® (upadacitinib) in the Treatment of Inflammatory Bowel Disease

FDA Approves Updated Indication for AbbVie’s RINVOQ® (upadacitinib) Expanding Access for Patients with Inflammatory Bowel Disease AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) updating the indication…

Read MoreFDA Approves Expanded Indication for RINVOQ® (upadacitinib) in the Treatment of Inflammatory Bowel Disease

Innate Pharma Schedules Analyst and Investor Event Focused on Lacutamab for October 28, 2025

Innate Pharma to Host Analyst and Investor Event Highlighting Lacutamab Clinical Data and Market Potential on October 28, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biopharmaceutical company focused on innovative immuno-oncology therapies, announced today that it…

Read MoreInnate Pharma Schedules Analyst and Investor Event Focused on Lacutamab for October 28, 2025

BeOne Medicines Secures FDA Breakthrough Therapy Designation for Sonrotoclax

BeOne Medicines Earns FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma, Strengthening Its Global Oncology Leadership BeOne Medicines Ltd., a leading global oncology-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has…

Read MoreBeOne Medicines Secures FDA Breakthrough Therapy Designation for Sonrotoclax

Genethon Reports 2-Year Efficacy of Low-Dose Gene Therapy GNT0004 in Duchenne Muscular Dystrophy

Genethon Presents 2-Year Efficacy Results of Low-Dose Micro-Dystrophin Gene Therapy (GNT0004) in Duchenne Muscular Dystrophy at ESGCT 2025 Genethon, a global leader in the research and development of gene therapies for rare genetic disorders, has reported encouraging long-term results from…

Read MoreGenethon Reports 2-Year Efficacy of Low-Dose Gene Therapy GNT0004 in Duchenne Muscular Dystrophy

Thermo Fisher Launches Molecular Microscope System for Lung Transplant Rejection Detection

Thermo Fisher Scientific Launches Molecular Microscope Diagnostic System to Transform Lung Transplant Rejection Detection and Management Thermo Fisher Scientific Inc., the global leader in serving science, has unveiled an innovative laboratory-developed test (LDT) that aims to revolutionize the detection and…

Read MoreThermo Fisher Launches Molecular Microscope System for Lung Transplant Rejection Detection

Charles River and Toxys Partner to Advance NAM-Based Developmental Toxicity Testing

Charles River and Toxys Partner to Advance NAM-Based Developmental Toxicity Testing Through ReproTracker® Collaboration Charles River Laboratories International, Inc. (NYSE: CRL) and Dutch biotechnology company Toxys have announced a strategic collaboration that aims to reshape the landscape of developmental and…

Read MoreCharles River and Toxys Partner to Advance NAM-Based Developmental Toxicity Testing
Cancer

Kairos Pharma Reports Positive Phase 2 Prostate Cancer Data at ESMO 2025

Kairos Pharma to Present Promising Phase 2 Prostate Cancer Data Highlighting Carotuximab’s Potential to Overcome Hormone Therapy Resistance at ESMO 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics that address treatment…

Read MoreKairos Pharma Reports Positive Phase 2 Prostate Cancer Data at ESMO 2025